Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH)

Not yet recruiting

Phase 2 Results N/A

Summary of Purpose

This is a randomized, placebo-controlled, subject- and investigator-blinded trial of BAF312 in intracerebral hemorrhage (ICH) patients to study efficacy, safety, and tolerability. BAF312 is a drug that could potentially limit brain inflammation after ICH, and thereby improve neurological outcome for hemorrhagic stroke patients. In this study, ICH patients meeting study criteria will be randomized at 1:1 ratio...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 8 November 2017.

14 Dec 2017 8 Nov 2017 9 Mar 2020 9 Mar 2020 1 Nov 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

Not available

Contacts

  • Novartis Pharmaceuticals